Angiogenesis in Gastric Cancer - An Overview

Introduction

Stool cancer, or gastric cancer, is one of the world's most common causes of cancer-related mortality. The prognosis for advanced stomach cancer is still not good, even with improvements in early identification and therapy. The process by which new blood vessels develop from pre-existing ones is known as angiogenesis, and it is essential to the development, spread, and metastasis of stomach cancer. The mechanics, clinical implications, and treatment approaches aimed at reducing angiogenesis in stomach cancer are all thoroughly explained in this article.

What Is Angiogenesis?

Angiogenesis is a multifaceted and intricate process controlled by the equilibrium of substances that promote and inhibit angiogenesis. Angiogenesis is regulated in normal physiology and mostly happens during wound healing and embryonic development. But in cancer, this mechanism becomes dysregulated, which results in the development of aberrant blood vessels that feed and oxygenate the tumor, promoting its growth and dissemination.

Vascular endothelial growth factors (VEGF), fibroblast growth factors (FGFs), platelet-derived growth factors (PDGF), angiopoietins, and matrix metalloproteinases (MMPs) are important factors in angiogenesis. The most effective and researched pro-angiogenic factor among them is VEGF.

What Are the Mechanisms of Angiogenesis in Gastric Cancer?

1. The VEGF Signaling Pathway: Endothelial cells have receptors for VEGF, which binds to them. This causes a series of signaling events that encourage the proliferation, migration, and survival of endothelial cells. The most researched isoform, VEGF-A, is strongly expressed in tissues from stomach cancers and is correlated with the angiogenesis, development, and metastasis of tumors. In particular, VEGFR-2 activation is crucial in the angiogenic process by improving endothelial cell function and vascular permeability.

2. Factor-1 Inducible by Hypoxia (HIF-1): Low oxygen levels in the tumor microenvironment, or hypoxia, are a major factor in the development of angiogenesis. Under hypoxic conditions, the transcription factor HIF-1 stabilizes and causes the overexpression of several pro-angiogenic genes, including VEGF. HIF-1α overexpression in gastric cancer has been associated with aggressive tumor angiogenesis and a poor prognosis.

3. MMPs, or Matrix Metalloproteinases: Enzymes known as MMPs break down elements of the extracellular matrix, which promotes the migration of endothelial cells and the creation of new blood vessels. In stomach cancer, MMP-2 and MMP-9, in particular, are overexpressed and aid in the angiogenesis and invasion of the tumor.

4. Growth Factor Derived from Platelets (PDGF): The recruitment of pericytes and smooth muscle cells, which stabilize newly created blood arteries, is facilitated by PDGF and its receptors (PDGFRs). In gastric cancer, elevated levels of PDGFRs and PDGF have been seen, which may facilitate the growth and vasculature of the tumor.

5. Growth factors for Fibroblasts (FGFs): FGFs promote the migration, differentiation, and proliferation of endothelial cells, especially FGF-2. In gastric cancer, FGF-2 is frequently overexpressed, which promotes angiogenesis and tumor growth.

What Are the Clinical Implications of Angiogenesis in Gastric Cancer?

The degree of angiogenesis present in a tumor is frequently associated with its prognosis, metastatic potential, and aggressiveness. Patients with stomach cancer who have high microvessel density (MVD), a marker of angiogenesis, typically have poorer prognoses. Thus, measuring angiogenesis can yield useful prognostic data and aid in treatment selection. Furthermore, angiogenesis is a major factor in treatment resistance to conventional medicines. Strong blood ties increase a tumor's ability to withstand and respond to therapies like radiation and chemotherapy, which target and kill rapidly proliferating cells. Thus, one effective treatment approach for stomach cancer is to target angiogenesis.

What Are the Therapeutic Targeting of Angiogenesis in Gastric Cancer?

With differing degrees of success, several anti-angiogenic agents have been developed and tested in gastric cancer. These agents fall into three categories: small compounds, tyrosine kinase inhibitors (TKIs), and monoclonal antibodies.

1. Monoclonal Antibodies:

• Bevacizumab: A monoclonal antibody that inhibits VEGF-mediated angiogenesis by targeting VEGF-A. Although Bevacizumab has been effective in treating a variety of malignancies, its benefits for gastric cancer have been negligible. Mixed results have been seen in clinical trials; some have improved progression-free survival but not overall survival.

• Ramucirumab: It targets VEGFR-2 and has shown more encouraging outcomes in treating gastric cancer. According to the results of the RAINBOW and REGARD trials, patients with advanced gastric cancer had better overall and progression-free survival when using ramucirumab alone or in conjunction with chemotherapy.

2. TKIs, or Tyrosine Kinase Inhibitors:

• Sunitinib and Sorafenib: Multi-targeted tyrosine kinases (TKIs) that block PDGFR, VEGFR, and other tyrosine kinases include sunitinib and sorafenib. These medications have a high level of toxicity and only modest results in treating stomach cancer.

• Apatinib: A selective VEGFR-2 inhibitor that has improved progression-free survival and overall survival in patients with advanced gastric cancer, demonstrating promising outcomes in phase III trials. Because of its oral delivery and good safety profile, apatinib is a viable treatment.

3. Additional Tiny Molecules: These immunomodulatory medications, thalidomide and lenidomide, have anti-angiogenic qualities. Specifically, thalidomide suppresses the FGF and VEGF signaling pathways. Although there isn't much use of them for stomach cancer, research is still being done to determine whether they could be beneficial.

What Are the Challenges and Future Directions?

• Resistance to Anti-Angiogenic Treatment: Through a variety of processes, including the activation of alternative angiogenic pathways, the recruitment of immune cells that are pro-angiogenic, and an increase in pericyte coverage, tumors can become resistant to anti-angiogenic therapy. Combination treatments may be able to overcome resistance and increase efficacy by focusing on several angiogenic pathways or combining anti-angiogenic drugs with immunotherapy or chemotherapy.

• Biomarkers for the Selection of Patients: Finding trustworthy indicators to forecast anti-angiogenic treatment response is essential. Biomarkers such as circulating VEGF levels, MVD, and genetic profiles can be used to customize therapy for each patient, improving results and reducing side effects.

• New Agents and Targets: Novel targets within the angiogenesis pathway are being investigated in ongoing research. Various phases of preclinical and clinical development are being undertaken by agents that target new signaling molecules, MMPs, and angiopoietins. Gaining insight into how the immune system and angiogenesis interact could lead to the development of novel combination treatments. Anti-angiogenic drugs can alter the environment surrounding tumors, which may improve the effectiveness of immune checkpoint inhibitors.

• Personalized Health Care: Proteomics and genomic technology developments are promising for customized medicine strategies in treating gastric cancer. Extensive molecular profiling of tumors can be used to pinpoint certain angiogenic drivers and adjust treatment plans accordingly.

Conclusion

Angiogenesis is essential to the etiology and development of stomach cancer. The complex web of signaling pathways that control angiogenesis provides a variety of options for therapeutic intervention. Even though the development of anti-angiogenic medicines has advanced significantly, issues like patient selection and resistance still exist. Prospective investigations centered around combination therapy, innovative targets, and personalized medicine methodologies exhibit the potential to enhance the prognosis of gastric cancer patients. It will be essential to comprehend and successfully target angiogenesis in the ongoing fight against this severe disease.